RedHill Biopharma (RDHL) Other Non-Current Assets (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Other Non-Current Assets data on file, last reported at $169000.0 in Q4 2025.

• On a quarterly basis, Other Non-Current Assets rose 14.19% year-over-year to $169000.0 in Q4 2025; TTM through Dec 2025 was $169000.0, a 14.19% increase from a year earlier, with the FY2025 full-year figure at $169000.0, up 14.19% from the prior year.
• Other Non-Current Assets for Q4 2025 stood at $169000.0, up from $160000.0 in the prior quarter.
• Over the last five years, Other Non-Current Assets for RDHL reached as high as $16.2 million in Q4 2021 and fell as low as $148000.0 in Q4 2024.
• Historically, Other Non-Current Assets has averaged $10.1 million across 5 years, with a median of $16.0 million in 2022.
• Across the five-year window, Other Non-Current Assets slumped 95.06% in 2023 and increased 14.19% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $16.2 million in 2021, then decreased by 1.05% to $16.0 million in 2022, then slumped by 95.06% to $790000.0 in 2023, then plunged by 81.27% to $148000.0 in 2024, then gained by 14.19% to $169000.0 in 2025.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $169000.0 in Q4 2025, $160000.0 in Q2 2025, and $148000.0 in Q4 2024.